Asthma | Treatment Algorithms: Claims Data Analysis | Pediatric Asthma | US | 2021

Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as ProAir HFA or its generics) and maintenance therapy to prevent exacerbations by targeting underlying pathophysiology (e.g., a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort). Many pediatric asthma patients receive more than one agent to treat their condition. Despite the availability of multiple well-established therapies, the pediatric asthma treatment landscape has seen the approval and launch of additional agents in recent years, including novel biologics (e.g., Regeneron / Sanofi’s Dupixent) and generic versions of the blockbuster inhaled drugs (e.g., albuterol sulfate and salmeterol / fluticasone propionate). These events have added more treatment options and fueled competition in this market.

Questions answered

  • What patient shares do key drugs garner by line of therapy in newly diagnosed pediatric asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric asthma patients?
  • How have newer biological therapies, such as AstraZeneca’s Fasenra or Dupixent, been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of pediatric asthma patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of pediatric asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


  • United States

Real world data

  • Longitudinal patient-level claims data analysis

Key drugs covered

  • Advair, Symbicort, Dulera, Breo, Dupixent, Fasenra, Nucala, Xolair, Ventolin, ProAir, albuterol sulfate, montelukast sodium, Flovent, Qvar, Spiriva

Key analysis provided

  • Brand / therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Login to access report